Navigation Links
Sinovac to Participate at 2010 Shanghai CPhI Exhibition
Date:5/26/2010

BEIJING, May 26 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading China-based vaccine manufacturer, announced today that the Company will participate at the 2010 Shanghai CPhI Exhibition, being held June 2-4, 2010. Sinovac's exhibition booth will be located in Hall E4, No. E4C42. At the exhibition, Sinovac will showcase its commercialized products, including its Healive, Anflu, Panflu and Panflu.1 vaccines.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, remarked, "We are excited to participate in the CPhI Exhibition in Shanghai, where we will feature our high quality products, such as vaccines against hepatitis A and seasonal influenza. As the exhibition attracts a global audience, we look forward to meeting with current and potential new international distribution partners to explore opportunities to further advance our global distribution strategy."

The Shanghai CPhI Exhibition provides Sinovac and other exhibitors/attendees with the opportunity to gain a better understanding of the global pharmaceutical industry. In 2009, a total of 1,651 exhibitors attended the event, including 127 overseas companies from 16 countries and regions. In addition to the exhibition booths, CPhI also hosted 54 high level conferences and seminars during the event, providing exhibitors and attendees with the opportunity to further communicate and exchange the latest information in the pharmaceutical industry.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines. Its 30%-owned joint venture, Sinovac Dalian, focuses on the research, development, manufacturing and commercialization of vaccines, such as rabies, chickenpox, mumps and rubella vaccines for human use.

About CPhI Worldwide

CPhI Worldwide was launched in 1990 as an international convention on pharmaceutical ingredients and intermediates. This inaugural CPhI attracted 250 visitors for the 16 exhibitors. Today this has grown to an unrivalled 24,000 industry professionals visiting some 1,500 exhibiting companies from over 125 countries. CPhI is the leading exhibition on pharmaceutical ingredients and allied industries. Each year the exhibition grows larger with exhibitors and visitors conducting significant levels of business at CPhI. Two sister events, ICSE and P-MEC now run alongside CPhI, a tripartite of events that is considered the must attend event for any individual or organisation within the pharmaceutical manufacturing community. In 2001 CPhI was launched in China. ICSE China was launched in 2005 and P-MEC China in 2006.

    For more information, please contact:

     Chris Lee
     Sinovac Biotech Ltd.
     Tel:   +86-10-8279-9659
     Fax:   +86-10-6296-6910
     Email: info@sinovac.com

    Investors:
     Amy Glynn/Stephanie Carrington
     The Ruth Group
     Tel:   +1-646-536-7023/7017
     Email: aglynn@theruthgroup.com
            scarrington@theruthgroup.com

    Media:
     Jason Rando
     The Ruth Group
     Tel:   +1-646-536-7025
     Email: jrando@theruthgroup.com


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac to Present at 2010 UBS Global Specialty Pharmaceuticals Conference
2. Sinovac Reports Unaudited First Quarter 2010 Financial Results
3. Sinovac to Host Conference Call to Report First Quarter 2010 Financial Results
4. Sinovac Announces Upsizing and Pricing of Common Share Offering
5. Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease
6. Sinovacs CEO Weidong Yin Presented with Annual Innovation Award by China Central Television
7. Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities
8. Sinovac Reports Unaudited Third Quarter 2009 Financial Results
9. Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government
10. Sinovac Receives Certificate of Approval to Distribute Panflu (H5N1) Vaccine in Hong Kong
11. Sinovac to Present at 2009 UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... NEWTOWN SQUARE, Pa. , June 20, 2017 /PRNewswire/ ... technology, is pleased to announce the issuance of a ... treating gout or hyperuricemia by the U.S. Patent and ... Biotech Inc., a winner of the Buzz of Bio ... , is akin to developing non-drug approaches to ...
(Date:6/20/2017)... ... June 20, 2017 , ... Do More with OHAUS , With the launch ... supplier in the weighing industry, to extending its expertise across the entire laboratory to ... hybridizations and more, allowing for its customers to 'Do More' in the ...
(Date:6/19/2017)... ... June 19, 2017 , ... As ... supporting EDETEK’s products including training, implementation, support, and client process and SOP development. ... He has previously held leadership roles for service providers and top-tier pharmaceuticals, and ...
(Date:6/19/2017)... ... June 19, 2017 , ... Tunnell Consulting ... 50 years. One of the biggest challenges faced by life sciences, biotech and pharmaceuticals ... services team is Kati Abraham , who is well known in the industry ...
Breaking Biology Technology:
(Date:3/22/2017)... , March 21, 2017 Optimove ... used by retailers such as 1-800-Flowers and AdoreMe, ... — Product Recommendations and Replenishment. Using Optimove,s machine learning ... personalized product and replenishment recommendations to their customers ... on predictions of customer intent drawn from a ...
(Date:3/20/2017)... March 20, 2017 At this year,s CeBIT Chancellor ... biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together with ... this year,s CeBIT partner country. At the largest German biometrics company the ... fingerprint, face and iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in ... ... combined in one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification ... Used combined in one project, multi-biometric solutions provide a ... ...
Breaking Biology News(10 mins):